Human papillomavirus genotype distribution in cervical samples collected in routine clinical practice at the Nantes University Hospital, France by Vaucel, Edouard et al.
Arch Gynecol Obstet (2011) 284:989–998
DOI 10.1007/s00404-010-1747-z
123
GYNECOLOGIC ONCOLOGY
Human papillomavirus genotype distribution in cervical samples 
collected in routine clinical practice at the Nantes University 
Hospital, France
Edouard Vaucel · Marianne Coste-Burel · 
Christian Laboisse · André Dahlab · Patrice Lopes 
Received: 24 April 2010 / Accepted: 21 October 2010 / Published online: 25 November 2010
© The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Objective The objective was to assess the human papillo-
mavirus (HPV) overall and type-speciWc prevalence in
smears collected during routine clinical practice.
Design HPV genotyping and smears were performed
independently between 2000 and 2006 for routine clinical
follow-up (primary screening and follow-up) in the Univer-
sity Hospital of Nantes, France.
Population All women with a cytological sample col-
lected no more than 12 months before HPV genotyping
were included.
Methods PCR was performed with MY09/MY11 primers
and genotyping by sequencing PCR product.
Main outcome measures Overall and genotype-speciWc
HPV prevalence were assessed according to cytological
diagnosis.
Results A total of 1,255 women were included (mean age
37.5 years). The proportion of high-risk (HR) HPV positive
samples increased according to cytological diagnosis
severity from 8% in normal specimens to 21% in atypical
squamous cells of undetermined signiWcance, 49% in low-
grade squamous intraepithelial lesion and 75% in high-
grade squamous intraepithelial lesion (HSIL) (p <0 . 0 0 1 ) .
Among 980 women with normal cytology, the overall HPV
prevalence varied according to age from 44% below
20 years to about 10% above 35 years (p <0 . 0 0 1 ) .  T h e
most prevalent HPV genotype in all cytological diagnoses
was HPV 16. HPV 53 appeared as the second most com-
mon genotype in normal cytological samples (10.9% of
HPV positive samples) but its prevalence decreased in
HSIL to less than 4%.
Conclusion The proportion of HR HPV positive women
increased according to cytological diagnosis severity. HPV
16 appeared as the most commonly encountered genotype
even when the diagnosis was normal. Its prevalence
increased with diagnosis severity hereby conWrming that
HPV 16 is more aggressive than other genotypes.
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Normal cytological diagnosis
Abbreviations
ASCUS Atypical squamous cells of undetermined 
signiWcance
CIN Cervical intraepithelial neoplasia
HPV Human papillomavirus
HSIL High-grade squamous intraepithelial lesion
ICC Invasive squamous cell carcinoma
LSIL Low-grade squamous intraepithelial lesion
Introduction
Human papillomavirus (HPV) genital infection is highly
prevalent among young sexually active women and represents
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the most common sexually transmitted infection [1–3]. It is
today universally accepted that HPV is associated with the
occurrence of cervical lesions, namely cervical intraepithe-
lial neoplasia (CIN) and invasive squamous cell carcinoma
(ICC) [4–6]. After infection, spontaneous viral clearance is
observed in most cases within 2 years [7–9]. However, after
persistent infection, cervical abnormalities may appear
which may progress to low (CIN1) or high-grade CIN
(CIN2/3) and ICC [10].
ICC represents the second most common cancer among
women worldwide [11] and accounts for 3,400 new cases
and about 1,000 deaths annually in France [12, 13]. Two
VLP L1 HPV vaccines are now available: an HPV 16/18
bivalent vaccine, Cervarix® for the prevention of HPV
16/18-related cervical precancerous lesions and an HPV
6/11/16/18 quadrivalent vaccine, Gardasil® which also
protects against vulvar and vaginal precancerous lesions,
and against HPV 6- and HPV 11-associated genital diseases
[14]. Recent French studies (EDiTH) reported that HPV
6/11/16/18 were found in 88% of cases with external
acuminata condylomata [15], 34% of low grade squamous
intraepithelial lesions (LSIL) [16], 64% of CIN2/3 [17] and
82% of ICC [18].
Pap smears are routinely used as secondary prevention
of CIN2/3 and cervical cancer. Although HPV genotype
distribution in speciWc cervical lesions has been widely
studied, HPV overall prevalence and type-speciWc preva-
lence in samples collected during routine clinical practice
remain poorly documented. The aim of this study was thus
to describe the HPV genotype distribution with special
focus on vaccinal HPV types in samples collected during
routine gynaecologic follow-up at the University Hospital
of Nantes, France.
Materials and methods
Data collection
Data from women seen at the Gynaecology outpatient
department, Nantes University Hospital, France, between
2000 and 2006 for a routine clinical follow-up were retro-
spectively collected from the hospital database. Information
had to include data on HPV genotype as well as a cytologi-
cal or histological diagnosis.
Cytological samples
Pap samples were routinely collected at the Department of
Gynaecology of the Nantes University Hospital as follows:
women with no cervical screening within the past 3 years
underwent a cervical smear performed using an Ayre spat-
ula and a cytobrush whereas no smear was performed in
women with screening history within the past 3 years,
except in case of clinical signs such as inXammatory pro-
cess or metrorrhagia.
Histological samples
Cervical biopsies were performed through colposcopy with
a micro-clip (2 £ 3 mm). Colposcopy was indicated in case
of abnormal smear such as atypical squamous cells of unde-
termined signiWcance (ASCUS), LSIL, or high-grade squa-
mous intraepithelial lesion (HSIL), or in presence of
oncogenic HPV type. Biopsy samples were taken from the
most acidophil area after applying acetic acid 3%, or on the
junctional area. Samples were immediately dropped in
formaldehyde.
Samples for HPV testing
HPV testing was systematically performed as part of the
routine gynaecologic follow-up, either during a screening
visit or a follow-up for cervico-vaginal lesion. Cervical
samples were collected with a bactopick swab or a cyto-
brush in 1 ml of sterile phosphate buVered saline solution
and transferred to the laboratory for HPV analysis.
HPV detection and genotyping
Total DNA was extracted from 200 l of the cell suspen-
sion using the MagNA Pure LC DNA isolation kit I (Roche
diagnostics) and ampliWed by real-time SYBR green PCR
with MY09/MY11 consensus primers on a rotorgen 3000
(Corbett Research). All samples were tested for the pres-
ence of human albumin gene by real-time PCR as described
previously to assess the sample quality [19].
Genotyping was performed by sequencing after puriWca-
tion of the PCR ampliWed product using the ABI PRISM
3100 (Applied Biosystems) with Big Dye terminator kit
(Applera). Sequences were then submitted to the NCBI
BLAST. HPV 16, 18, 31, 33, 35, 39, 45, 52, 53, 58, 66, 68,
73 and 82 were classiWed as high-risk genotypes whereas
HPV 6, 11, 44, 54, 61, 62, 70, 71, 72, 81, 83, 84 and 87
were considered as low-risk genotypes.
Selection of swabs and biopsies
Since mean time to HPV clearance after infection ranges
from about 13 to 19 months [9], we only considered cervi-
cal swabs or biopsies collected no more than 12 months
before HPV genotyping. Therefore, for each woman, sam-
ples collected more than 12 months before genotyping and
samples collected after HPV genotyping (with a 20 days
margin) were not considered for the analysis. Women who
underwent treatment for their cervical lesion prior to HPVArch Gynecol Obstet (2011) 284:989–998 991
123
genotyping were also excluded from the analysis. The
inclusion algorithm is presented on Fig. 1.
Cytological and histological diagnoses
Cytological specimens were classiWed according to the
2001 Bethesda classiWcation [20] as follows: normal,
ASCUS, LSIL, or HSIL. When several cytological samples
were available for a single woman, the most pejorative
diagnosis was kept for the analysis. Histological specimens
were classiWed according to the Richart classiWcation [21]
as either normal, CIN1, CIN2, CIN3, or ICC.
Two separate analyses of HPV genotype distribution
were conducted, one on women with available cytological
diagnosis, the other on women with available histological
data.
Statistical analysis
Qualitative variables were described with the number of
cases and the proportions. For quantitative variables, mean
and range were given. A 2 for trend analysis was per-
formed to study the association between HPV positivity
and severity of diagnosis. Statistical analysis was per-
formed with SAS® v.8.02 and AdClin® v.3.1. The ratio of
HPV 16 prevalence in CIN3 versus CIN1 and versus nor-
mal histology together with its 95% conWdence interval was
calculated to appreciate the importance of this genotype in
the risk of severe histological lesions.
Ethics and consent
According to the French legislation (Public Health Code
modiWed by the law No. 2004-806, 9 August 2004 and the
Huriet-Sérusclat act 88-1138, 20 December 1988, and since
this study was conducted during patients’ routine clinical
follow-up without any modiWcation, no ethics committee
approval was necessary. All women gave their oral consent
for HPV testing.
Results
A total of 1,257 women were included in the analysis
according to cytological diagnosis. In parallel, 482 women
were included according to histological diagnosis.
Results according to cytological diagnosis
Among women with cytological diagnosis, two were
excluded because they underwent cervical treatment prior
to HPV genotyping. Mean age of the 1,255 remaining
women was 37.5 years (range 15–86) and varied signiW-
cantly from 32 years in LSIL to 38.5 years in HSIL
Fig. 1 Inclusion algorithm992 Arch Gynecol Obstet (2011) 284:989–998
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(p < 0.001). The mean delay between cytological diagnosis
and genotyping was 12 § 40 days. In 980 women (78%),
the cytological diagnosis was normal whereas 141 (11%)
had an ASCUS, 98 (8%) an LSIL, and 36 (3%) an HSIL
(Table 1).
Overall HPV prevalence
Among all 1,255 women, 265 (21%) were HPV positive.
This proportion increased signiWcantly according to cyto-
logical diagnosis severity from 13% in normal specimens to
30% in ASCUS, 69% in LSIL and 75% in HSIL (2 for
trend analysis gave p < 0.001; Table 2). Multiple HPV
infection was present in approximately 6% of all HPV pos-
itive samples with a higher prevalence in ASCUS (17%).
Among the 265 HPV positive samples, 184 (69%) had at
least one high-risk genotype.
Women with normal cytological diagnosis
Mean age of women with normal cytological diagnosis was
38.5 years. About 13% of these 980 women were HPV pos-
itive, 3% of them as a multiple HPV infection. The propor-
tion of HPV positive women varied signiWcantly according
to age with the highest prevalence (44%) observed below
20 years of age. Thereafter, the prevalence decreased with
increasing age reaching about 10% above 35 years
(p < 0.001). Eighty women (8.2%) had at least one high-
risk genotype. This proportion decreased signiWcantly with
age from 24% in women below 25 years of age to 6.5% in
Table 1 Characteristics of women with normal cytological diagnosis, atypical squamous cells of undetermined signiWcance (ASCUS), low-grade
squamous intraepithelial lesion (LSIL), or high-grade squamous intraepithelial lesion (HSIL)
Percentages are given within parentheses
Cytological diagnosis Total
Normal ASCUS LSIL HSIL
Number of women (%) 980 (78.1) 141 (11.2) 98 (7.8) 36 (2.9) 1,255 (100)
Mean age in years (range) 38.5 (17–86) 33.9 (16–80) 32.0 (15–58) 38.5 (19–73) 37.5 (15–86)
Age distribution, n (%)
<20 years 18 (1.8) 6 (4.3) 6 (6.1) 1 (2.8) 31 (2.5)
20–24 61 (6.2) 26 (18.4) 21 (21.4) 2 (5.6) 110 (8.8)
25–29 121 (12.3) 21 (14.9) 20 (20.4) 5 (13.9) 167 (13.3)
30–34 199 (20.3) 25 (17.7) 13 (13.3) 8 (22.2) 245 (19.5)
35–39 165 (16.8) 23 (16.3) 17 (17.3) 4 (11.1) 209 (16.7)
40–44 158 (16.1) 20 (14.2) 11 (11.2) 6 (16.7) 195 (15.5)
45–49 95 (9.7) 8 (5.7) 5 (5.1) 4 (11.1) 112 (8.9)
¸50 163 (16.6) 12 (8.5) 5 (5.1) 6 (16.7) 186 (14.8)
Table 2 Overall HPV prevalence and prevalence of HPV 6, 11, 16, and 18 among women with normal cytological diagnosis, ASCUS, LSIL, or
HSIL
The number of cases is given as well as the prevalence among all samples (within parentheses) and the prevalence among HPV positive women
(within parentheses and italics)
a Women infected by at least one high-risk genotype
b Women infected by one or several low-risk genotype(s) without high-risk genotype
Total samples 
(n = 1,255)
Cytological diagnosis
Normal (n = 980) ASCUS (n = 141) LSIL (n = 98) HSIL (n =3 6 )
HPV positive 265 (21.1) (100) 128 (13.1) (100) 42 (29.8) (100) 68 (69.4) (100) 27 (75.0) (100)
High-risk HPVa 184 (14.7) (69.4) 80 (8.2) (62.5) 29 (20.6) (69.0) 48 (49.0) (70.6) 27 (75.0) (100)
Low-risk HPVb 65 (5.2) (24.5) 34 (3.5) (26.6) 12 (8.5) (28.6) 19 (19.4) (27.9) 0 (0.0) (0.0)
HPV 6 total 26 (2.1) (9.8) 10 (1.0) (7.8) 7 (5.0) (16.7) 9 (9.2) (13.2) 0 (0.0) (0.0)
HPV 11 total 6 (0.5) (2.3) 2 (0.2) (1.6) 2 (1.4) (4.8) 2 (2.0) (2.9) 0 (0.0) (0.0)
HPV 16 total 90 (7.2) (34.0) 35 (3.6) (27.3) 19 (13.5) (45.2) 20 (20.4) (29.4) 16 (44.4) (59.3)
HPV 18 total 12 (1.0) (4.5) 6 (0.6) (4.7) 0 (0.0) (0.0) 4 (4.1) (5.9) 2 (5.6) (7.4)
HPV 16 and/or 18 total 100 (8.0) (37.7) 40 (4.1) (31.3) 19 (13.5) (45.2) 23 (23.5) (33.8) 18 (50.0) (66.7)Arch Gynecol Obstet (2011) 284:989–998 993
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women over 25 years (p < 0.001; Fig. 2). The most preva-
lent HPV genotypes were by descending order of frequency
HPV 16 (3.6%), HPV 53 (1.4%), HPV 6 (1.0%), HPV 31
(0.9%) and HPV 33 (0.7%) (Fig. 3). The prevalence of
HPV 6, 11, 16, and 18 is given in Table 2. At least one of
these four genotypes, associated or not with another HPV
type was present in 5.3% of samples with normal cytology.
Women with ASCUS diagnosis
Mean age of the 141 women with an ASCUS was 34 years.
Among these women, 42 (30%) were HPV positive, of
whom 35 (83%) were infected by a single HPV type.
Among HPV positive women with ASCUS, 69% had at
least one high-risk genotype. The most prevalent HPV
Fig. 2 Distribution of high-risk 
and low-risk HPV genotypes 
according to age in women with 
normal cytological diagnosis 
(n = 980)
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cervical samples with normal cytological diagnosis (a), ASCUS (b),
LSIL (c) and HSIL (d). Red bars indicate high-risk genotypes, blue
bars low-risk genotypes. Prevalence is given as the proportion of each
speciWc HPV genotype among HPV positive samples
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types were HPV 16 (n = 19, 13% of all ASCUS, 45% of
HPV positive ASCUS), HPV 6 (n = 7), HPV 53 (n =5 ) ,
HPV 31 and HPV 33 (n = 3) (Fig. 3). HPV 6 and/or 11 and/or
16 and/or 18 were present in 20% of all ASCUS cases and
67% of HPV positive ASCUS.
Women with LSIL diagnosis
Women with LSIL diagnosis were younger than the aver-
age with a mean age of 32 years. Among these 98 women,
69% were HPV positive of whom 93% as a monoinfection.
Seventy-one percent of HPV positive LSIL cases were
infected with at least one high-risk HPV type. Most fre-
quently encountered HPV genotypes in LSIL were HPV 16
(n = 20, 20% of all LSIL, 29% of HPV positive LSIL),
HPV 53 and HPV 6 (n = 9), HPV 66 (n = 5) and HPV 18
(n = 4). Alone or in association with other HPV types, HPV
6 and/or 11 and/or 16 and/or 18 were found in 35% of all
LSIL and 50% of HPV positive LSIL cases.
Women with HSIL diagnosis
Thirty-six women had an HSIL diagnosis. Mean age was
38.5 years. Seventy-Wve percent were HPV positive, almost
all of them (96%) with an HPV monoinfection. All HPV
positive HSIL specimens were infected by at least one
high-risk HPV genotype. Most frequent genotypes were
HPV 16 (n = 16, 44% of all HSIL, 59% of HPV positive
HSIL), HPV 58 (n = 5), HPV 18 and HPV 52 (n =2 )
(Fig. 3). HPV 6 and/or 11 and/or 16 and/or 18 were found
in 50% of all HSIL and in 67% of HPV positive HSIL.
Results according to histological diagnosis
Among women with histological data, 59 were excluded,
25 because of cervical treatment prior to HPV genotyping
and 34 because of undetermined histological diagnosis
(Fig. 1). Characteristics of the 423 remaining women
are presented in Table 3. Mean age was 34 years (range
16–64) and varied from 32.5 years in CIN1 to 44 years in
women with cancer diagnosis. The mean delay between
biopsy and HPV genotyping was 15.5 days (range ¡20 to
363). In 163 women (39%), the diagnosis was normal
whereas 117 women (28%) had a CIN1, 79 (19%) had a
CIN2 and 62 (15%) had a CIN3. Only two cases had an
ICC diagnosis.
Overall HPV prevalence
Among all 423 women, 228 (54%) were HPV positive.
This proportion increased signiWcantly with increasing
diagnosis severity from 33% in normal histological
specimens, 55% in CIN1, 68% in CIN2, and 89% in CIN3
(2 for trend gave p < 0.001; Table 4). Multiple HPV infec-
tion was found in approximately 11% of HPV positive
cases with the highest prevalence observed in CIN2 (17%).
Among HPV positive specimens, 85% were infected by at
least one high-risk type.
Women with normal histological diagnosis
Histological diagnosis was normal in 163 women (mean
age 34.7 years) of whom 54 (33%) were HPV positive.
Among these HPV positive women, 91% were infected
by a single HPV type. At least one high-risk genotype
was found in 24% of biopsies with normal diagnosis. The
most common HPV genotypes were HPV 16 (n = 10, 6%
of normal biopsies, 19% of HPV positive normal biop-
sies), HPV 53 (n = 9), HPV 18 and HPV 6 (n =6 )
(Fig. 4). HPV 6, 11, 16 and/or 18 were found in 14% of
normal histological specimens and 43% of HPV positive
normal biopsies.
Table 3 Characteristics of women with normal histological diagnosis, low-grade cervical intraepithelial neoplasia (CIN1), CIN2, CIN3,
or invasive squamous cell carcinoma (ICC)
Percentages are given within parentheses
Histological diagnosis Total
Normal CIN1 CIN2 CIN3 ICC
Number of women (%) 163 (38.5) 117 (27.7) 79 (18.7) 62 (14.7) 2 (0.5) 423 (100)
Mean age in years (range) 34.7 (16–64) 32.6 (17–60) 32.8 (18–54) 36.1 (19–57) 44.0 (31–57) 34.0 (16–64)
Age distribution, n (%)
<20 years 4 (2.5) 7 (6.0) 2 (2.5) 1 (1.6) 0 (0.0) 14 (3.3)
20–24 24 (14.7) 22 (18.8) 12 (15.2) 5 (8.1) 0 (0.0) 63 (14.9)
25–29 30 (18.4) 18 (15.4) 17 (21.5) 9 (14.5) 0 (0.0) 74 (17.5)
30–34 34 (20.9) 23 (19.7) 14 (17.7) 12 (19.4) 1 (50.0) 84 (19.9)
35–39 20 (12.3) 20 (17.1) 17 (21.5) 14 (22.6) 0 (0.0) 71 (16.8)
¸40 51 (31.3) 27 (23.1) 17 (21.5) 21 (33.9) 1 (50.0) 117 (27.7)Arch Gynecol Obstet (2011) 284:989–998 995
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Women with CIN1 diagnosis
A CIN1 diagnosis was found in 117 women (mean age
32.6 years) of whom 64 (55%) were HPV positive. Among
these HPV positive women, 90% had a monoinfection. At
least one high-risk genotype was found in 40% of CIN1.
Most frequent genotypes were HPV 16 (n = 17, 15% of
CIN1, 27% of HPV positive CIN1), HPV 53 (n =1 0 ) ,  H P V
6 (n = 7), and HPV 18, 31, and 66 (n = 5). HPV 6, 11, 16
and/or 18 were present in 26% of CIN1 and 47% of HPV
positive CIN1 specimens.
Women with CIN2 or CIN3 diagnosis
CIN2 and CIN3 were found in 79 and 62 women with his-
tological diagnosis. Mean age was 32.8 and 36.1 years,
Table 4 Overall HPV prevalence and prevalence of HPV 6, 11, 16, and 18 among women with normal histological diagnosis, CIN1, CIN2, or
CIN3
The number of cases is given as well as the prevalence among all samples (within parentheses) and the prevalence among HPV positive women
(within parentheses and italics)
a Women infected by at least one high-risk genotype
b Women infected by one or several low-risk genotype(s) without high-risk genotype
Total samples 
(n = 423)
Histological diagnosis
Normal (n = 163) CIN1 (n = 117) CIN2 (n =7 9 ) C I N 3  ( n =6 2 )
HPV positive 228 (53.9) (100) 54 (33.1) (100) 64 (54.7) (100) 54 (68.4) (100) 55 (88.7) (100)
High-risk HPVa 193 (45.6) (84.6) 39 (23.9) (72.2) 47 (40.2) (73.4) 54 (68.4) (100) 53 (85.5) (96.4)
Low-risk HPVb 29 (6.9) (12.7) 13 (8.0) (24.1) 14 (12.0) (21.9) 0 (0.0) (0.0) 2 (3.2) (3.6)
HPV 6 total 15 (3.5) (6.6) 6 (3.7) (11.1) 7 (6.0) (10.9) 2 (2.5) (3.7) 0 (0.0) (0.0)
HPV 11 total 3 (0.7) (1.3) 1 (0.6) (1.9) 2 (1.7) (3.1) 0 (0.0) (0.0) 0 (0.0) (0.0)
HPV 16 total 88 (20.8) (38.6) 10 (6.1) (18.5) 17 (14.5) (26.6) 25 (31.6) (46.3) 35 (56.5) (63.6)
HPV 18 total 19 (4.5) (8.3) 6 (3.7) (11.1) 5 (4.3) (7.8) 7 (8.9) (13.0) 1 (1.6) (1.8)
HPV 16 and/or 18 total 105 (24.8) (46.1) 23 (14.1) (42.6) 21 (17.9) (32.8) 31 (39.2) (57.4) 36 (58.1) (65.5)
Fig. 4 Prevalence of most frequently encountered HPV genotypes in
cervical samples with normal histological diagnosis (a), CIN1 (b),
CIN2 (c) and CIN3 (d). Red bars indicate high-risk genotypes, blue
bars low-risk genotypes. Prevalence is given as the proportion of each
speciWc HPV genotype among HPV positive samples
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respectively. Prevalence of HPV positive CIN2 and CIN3
specimens was 68 and 89%, respectively (Table 4). Mono-
infection was observed in 83% of HPV positive CIN2 and
in 91% of CIN3. At least one high-risk genotype was found
in 68% of CIN2 and in 86% of CIN3 specimens. Most com-
mon HPV genotypes in CIN2 were HPV 16 (n = 25, 32%
of CIN2, 46% of HPV positive CIN2) followed by HPV 18
(n = 7), HPV 66 (n = 6) and HPV 33 (n =5 )  ( F i g .4). In
CIN3, HPV 16 was by far the most commonly observed
genotype (n = 35, 57% of CIN3, 64% of HPV positive
CIN3), followed by HPV 58 (n = 8), HPV 31 (n =5 )  a n d
HPV 53, HPV 33 and HPV 52 (n = 2). HPV 6 and/or 11
and/or 16 and/or 18 were found in 41% of CIN2 and 58%
of CIN3 and in 59 and 65% of HPV positive CIN2 and
CIN3, respectively. Only one case (CIN2) had a co-infec-
tion involving HPV 6 (or HPV 11) with a high-risk HPV
type (HPV 6 + HPV 39). The ratio of HPV 16 prevalence in
CIN3 versus CIN1 was 3.89 (95% CI [2.38–6.35]) and the
ratio of HPV 16 prevalence in CIN3 versus normal histol-
ogy 9.20 (95% CI [4.86–17.4]).
Discussion
Based on a large number of subjects, our study reports the
HPV overall prevalence and HPV genotype distribution in
cytological and histological specimens collected in routine
clinical practice in a hospital-based gynaecologic depart-
ment.
Among all 1,255 women, the observed proportion of
those with abnormal smears (22%) is much higher than that
previously reported by Bergeron et al. in France (3–4%)
[22, 23]. This discrepancy may result from diVerences in
the recruitment of patients. In each Bergeron study, approx-
imately 200,000 smears were collected from public or pri-
vate structures whereas in the present study, the recruitment
was hospital-based with as a result, inclusion of more
severe cases. Since it is hospital-based, our study popula-
tion is thus not representative of the general population.
However, our results depict university hospital routine clin-
ical practice. Noteworthy, the diagnosis distribution among
abnormal cytological samples is rather similar to
Bergeron’s data with approximately 50% of ASCUS, 36%
of LSIL, and 13% of HSIL.
As expected, the prevalence of HPV positive samples
increases with increasing diagnosis severity. In cytological
samples, the overall HPV prevalence varies indeed from
13% in normal samples to 70–75% in LSIL and HSIL. In
ASCUS cases, the prevalence is in-between at approxi-
mately 30%. In histological samples, the overall HPV prev-
alence increases with the severity of the lesion reaching a
maximum of 89% in CIN3 cases. The HPV prevalence
observed in normal histological specimens (33%) is higher
than that in normal cytological samples (13%). This may be
explained by the fact that biopsy was performed in case of
abnormal smear, clinical sign, or presence of oncogenic
HPV type.
The overall HPV prevalence in women with normal
cytological diagnosis observed in our study is twice higher
than that reported in the US by Castle et al. in about
800,000 smears collected from women above 30 years of
age [24]. The authors observed indeed that 4% of women
with normal smears were carcinogenic HPV positives
whereas the prevalence of high-risk HPV genotypes in this
subgroup reached 8.2% in our cohort. This higher preva-
lence could be partly explained by the hospital-based
recruitment in our study and by the diVerent age distribu-
tion between cohorts. In France, a previous study based on
2,145 smears without lesion [25] collected from women
above 30 years who underwent their biennial or triennial
routine screening in the university hospital of Reims,
reported that high-risk HPV genotypes were found in
10.8% of cases which is close to our Wndings. Another
French study on 3,640 women (above 20 years of age) with
normal cytology enrolled either from the university hospital
of Amiens or from private gynaecologists, reported a high-
risk HPV prevalence of 13.5% [26]. In a meta-analysis
based on 157,879 women with normal cervical cytology
[27], the overall HPV prevalence was estimated to be
10.4% (8% in Europe). The high-risk HPV prevalence
observed in our subgroup of women with normal cytologi-
cal diagnosis appears thus similar to that reported earlier. In
the present study, presence of high-risk genotypes in
women with normal smears is highly associated with age
with a prevalence decreasing from 24% to 6.5% before and
after 25 years of age, respectively. Based on a rather large
number of women with normal cytological diagnosis
(n = 980), our study stresses the fact that a substantial pro-
portion of these women is infected by a high-risk HPV, this
proportion exceeding 20% in women below 25 years of
age. Such a high prevalence of HPV in younger women
with normal cytology was already reported by De Sanjosé
et al.  [27] in the above mentioned meta-analysis.
On the other hand, the overall HPV prevalence in
women with abnormal cytological or histological diagnosis
is somehow lower in our study than what was previously
reported in the literature. In CIN2/3 specimens for example,
the observed prevalence of 77% is much lower than the
98% reported by Pretet et al. [17]. The same is true for the
HPV prevalence in LSIL (69 versus 98%) [16]. A possible
explanation is that in the present study, cytological or histo-
logical diagnosis and genotyping were possibly made on
diVerent samples and at diVerent time points. These two
parameters were associated with each other by linkage of
the hospital genotype and diagnosis databases. Even if
HPV infection is known to last for about 13–19 months [9],Arch Gynecol Obstet (2011) 284:989–998 997
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one can not exclude that HPV clearance occurred between
diagnosis and genotyping. However, this hypothesis is
unlikely since the mean delay between cytological diagno-
sis and genotyping (15 days) or between histological diag-
nosis and genotyping (11 days) is rather short. The HPV
negative status of some cervical cell suspension specimens
with severe dysplasia could instead result from a low HPV
viral load or from the fact that some genotypes are not
matched by the MY09/MY11 primers. A reasonable expla-
nation for these discrepancies in HPV prevalence is indeed
the use of HPV detection methods of diVerent sensitivity
[18]. Such diVerences in sensitivity and characteristics of
PCR systems for the detection of HPV within clinical sam-
ples have been previously described and there is good evi-
dence that some genotypes are better matched to the
consensus primer pools than others [28–31]. To cope with
these diVerences in sensitivity, we also provided genotype-
speciWc prevalence data among HPV positive women.
HPV 16 was by far the most commonly encountered
genotype in cervical smears and histological specimens
even when the diagnosis was normal. Figures 3 and 4
clearly show that the prevalence of HPV 16 increases with
increasing diagnosis severity hereby conWrming that HPV
16 tends to persist longer and is more aggressive than other
genotypes [32]. Since the overall HPV prevalence in
women with abnormal smears in our study is lower than
previously reported, we considered HPV positive samples
to calculate the prevalence of each speciWc genotype. Doing
so, the prevalence of HPV 16 in LSIL, CIN2 and CIN3
becomes of the same magnitude as what was previously
observed [16, 17]. HPV 16 was indeed found in 29% of our
LSIL cases which is very close to results reported in the
meta-analysis by CliVord et al. (27%) [33]. To illustrate the
high pathogenic role of HPV 16, we calculated the ratio of
HPV prevalence in CIN3 versus normal histology and ver-
sus CIN1. These ratios indicate that HPV 16 is almost four-
fold more prevalent in CIN3 than in CIN1 and about nine-
fold more prevalent in CIN3 than in normal histological
samples hereby conWrming that this genotype is associated
with lesions presenting a high probability of progression to
severe forms. Although the number of cases is limited,
HPV 53 appears as the second most common genotype in
normal cytological samples and in LSIL (11 and 13%,
respectively) and as the third most common in ASCUS
(12%). However, the prevalence decreases in HSIL to less
than 4%, suggesting that samples infected with HPV 53 are
at low risk of progression towards severe forms although
some few cases of cervical cancer following HPV 53 mon-
oinfection have been described [18]. The same phenome-
non is observed for biopsies in which HPV 53 is frequently
encountered in normal and CIN1 specimens (16%) and
much less prevalent in CIN2 and CIN3 (below 4%). Alone
or in association, HPV 6, 11, 16 and/or 18 are found in over
50% of HPV positive cytological and histological speci-
mens hereby suggesting that a substantial proportion of
these lesions could be avoided by a quadrivalent HPV vac-
cination.
Despite some methodological limitations, our study pro-
vides accurate French data on HPV genotype distribution in
samples collected during routine hospital-based gynaeco-
logic follow-up and brings further evidence of the potential
impact of a quadrivalent vaccination.
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